Our company is dedicated to providing molecular imaging technology that combines functional and structural imaging - PET/CT, which uses imaging methods to display specific molecules at the tissue, cellular and subcellular levels, reflecting changes in the molecular level and their biological behavior in vivo. Qualitative and quantitative imaging studies enable a new "precision pharmacology" that addresses the core issues of drug discovery.
Service Overview
One of the most cutting-edge medical imaging technologies now on the market is PET/CT testing technology, which combines two potent imaging modalities. Positional imaging (PET) displays the body's metabolic activity, including both normal and pathological tissue activity (tumors); computed tomography (CT) scans display the intricate anatomical structures of these same regions. With a high degree of certainty, a variety of malignancies can be found, located, and their stages evaluated using the information from PET/CT scans.
Integrated PET/CT provides accurate tumor detection and localization for a wide range of cancers including: brain, chest, cervical spine, colorectal, esophagus, stomach, head and neck, lung, lymphoma, melanoma, ovary, pancreas, kidney, and more.
Our company provides molecular imaging drug discovery outsourcing, drug radiolabel synthesis, novel PET imaging agent research, and targeted therapy technology services for oncology treatment. We provide preclinical imaging, radiochemistry and data analysis. Our comprehensive imaging solutions include:
- Animal model imaging acquisition.
- Pharmaceutical radiochemistry and preclinical pharmacokinetic and pharmacodynamic imaging services.
- Establishment of high-end image data analysis platforms.
Overall Solutions
At Our company's PET Molecular Imaging Center, our PET-CT services are equipped with state-of-the-art equipment. Our research team not only has expertise in handling the most complex formulations, but also has extensive experience in the pharmaceutical industry and contract service organizations.
Our laboratories are cGMP compliant and equipped with the most advanced analytical instruments. In addition, we are able to develop tailor-made analytical methods to meet your specific needs
| Project Name | PET-CT Service |
| Service Details | - Radionuclides can be used to assess specific metabolism or synthesis rates, allowing for assessment of the functional status and integrity of tissues.
- Radioligands can be used to measure the concentration of specific receptor or transporter sites so that the integrity or distribution of specific targets that may correspond to their expression can be assessed.
- Quantitative model chamber analysis methods can be used to account for possible confusion caused by blood flow differences.
- Radiotracer-labeled PET studies allow quantitative assessment of drug pharmacokinetics and metabolism.
- Combined with pharmacodynamic data such as behavioral, pharmacokinetic PET studies can help researchers establish dose-effect relationships and dose determinations.
- Also, PET can track the regional distribution of drugs in target tissues.
|
| Deliverables | Original images and raw data.
A complete experimental report, including experimental materials, experimental procedures, and experimental results. |
| Cycle | Decide according to your needs. |
Fig 1. Summed 5- to 10-min dynamic 18F-fluciclovine PET and fused PET/CT images of a patient with oestrogen receptor-positive IDC. (Scott N. P, et al. 2022)
For more information, please feel free to contact us.
Reference
- Scott N. P, et al. (2022). "Characterising 18F-Fluciclovine Uptake in Breast Cancer through The Use of Dynamic PET/CT Imaging" British Journal of Cancer . 126: 598-605.
Related Services
It should be noted that our service is only used for research, not for clinical use.
